Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCUQ32
|
|||
| Drug Name |
Runimotamab
|
|||
| Synonyms |
RG6194
Click to Show/Hide
|
|||
| Drug Type |
Bispecific antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1 | [1] | |
| Company |
Roche/Genentech
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03448042) A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023 Feb;22(2):101-126. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.